New Hope for Rare Anal Cancer as Zynyz Nears EU Approval

MORGES, Switzerland – January 30, 2026 – European patients with an advanced and difficult-to-treat form of anal cancer may soon have a powerful new first-line treatment option, following a landmark recommendation from a key regulatory body. In a significant step forward for a disease that has seen little therapeutic innovation for decades, Incyte's immunotherapy drug Zynyz® (retifanlimab) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

The committee recommended approving Zynyz in combination with standard platinum-based chemotherapy for adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). This positive opinion paves the way for a final decision from the European Commission, which typically follows the CHMP’s guidance and could make Zynyz the first approved immunotherapy combination for this specific patient group in the European Union.

“Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International, in a statement. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.”

A Breakthrough for a Neglected Disease

Squamous cell carcinoma of the anal canal is a rare but life-threatening malignancy, accounting for about 85% of all anal cancer cases. While considered rare, with an incidence of one to two cases per 100,000 people, its rate has been climbing by approximately 3% annually over the past decade. The primary risk factor is human papillomavirus (HPV) infection, which is associated with about 90% of cases.

One of the greatest challenges in treating SCAC is that its symptoms—such as pain, itching, or changes in bowel movements—often mimic more common, benign conditions like hemorrhoids. This can lead to significant delays in diagnosis, with a majority of patients already presenting with locally advanced disease when they first seek medical care. For the roughly 25% of patients whose cancer has spread to distant parts of the body (metastatic disease), the prognosis is particularly grim, with five-year survival rates plummeting to between 15% and 20%.

For decades, the standard-of-care for advanced SCAC has remained largely unchanged, relying on chemotherapy and radiation. For patients with metastatic disease, options have been mostly palliative, aimed at managing symptoms rather than providing a cure. The lack of authorized medicines specifically for advanced SCAC in the EU has created a profound unmet medical need, leaving patients and clinicians desperate for new, more effective therapies.

The Science Behind the Success

The CHMP's positive opinion is anchored in the robust results of the Phase 3 POD1UM-303/InterAACT2 trial, the largest randomized study ever conducted for this disease. The global trial evaluated the efficacy and safety of adding Zynyz, a PD-1 inhibitor, to a standard chemotherapy regimen of carboplatin and paclitaxel.

Zynyz works by blocking the programmed death receptor-1 (PD-1), a protein on immune T-cells that cancer cells often exploit to evade attack. By inhibiting this pathway, the drug effectively unleashes the body's own immune system to recognize and destroy malignant cells. This mechanism has proven successful across a range of cancers, and its efficacy in an HPV-driven cancer like SCAC is built on a strong scientific rationale.

Data from the trial, published in The Lancet, demonstrated a clear and statistically significant benefit. Patients who received the Zynyz-chemotherapy combination experienced a 37% reduction in the risk of disease progression or death compared to those who received chemotherapy plus a placebo. The median progression-free survival (PFS)—the length of time patients lived without their cancer worsening—was extended to 9.3 months in the Zynyz group, a meaningful improvement over the 7.4 months seen in the placebo group.

Furthermore, the objective response rate (ORR), or the percentage of patients whose tumors shrank, was 56% for the Zynyz combination versus 44% for the chemotherapy-alone arm. While data on overall survival (OS) is still maturing, an interim analysis showed a promising trend, with a median OS of 29.2 months for the Zynyz group compared to 23.0 months for the control group. Although this difference was not yet statistically significant, the EMA concluded that when viewed alongside the strong PFS data, the overall benefit of Zynyz was clear.

Navigating the Regulatory and Market Landscape

With the CHMP's positive opinion in hand, the path to market access in Europe is now well-defined. The European Commission, which holds the authority to grant marketing authorization for all centrally authorized products in the EU, will now review the recommendation. This process is typically a formality, with a final decision expected within approximately 67 days, potentially positioning Zynyz for a European launch by the spring of 2026.

If approved, Zynyz would not only be the first PD-1 immunotherapy combination for first-line advanced SCAC in Europe but would also establish a new benchmark for treatment. This represents a significant commercial opportunity for Incyte, allowing it to address a critical gap in the oncology market. While SCAC is a rare disease, its rising incidence and the lack of effective treatments mean a new, proven therapy could see rapid adoption by clinicians.

The approval would bolster Incyte's growing oncology portfolio in Europe, where Zynyz is already approved for another rare skin cancer, Merkel cell carcinoma. It also aligns with the company's global strategy, as the drug is already approved for certain SCAC patient populations in the United States and Japan.

Clinical Perspective and Future Outlook

Oncologists specializing in gastrointestinal cancers have hailed the POD1UM-303 trial as a landmark study. According to one expert familiar with the data, the results are practice-changing. Because it is the first successful Phase 3 trial of a checkpoint inhibitor in this setting, the combination of Zynyz with chemotherapy is poised to become the new global standard of care for patients with previously untreated advanced SCAC.

The addition of immunotherapy was found to be generally well-tolerated. The trial reported no new safety signals, though the combination did lead to a higher rate of serious adverse events compared to chemotherapy alone (47% vs. 39%). The most frequent serious issues included sepsis, pulmonary embolism, diarrhea, and vomiting, which are known risks associated with both chemotherapy and immunotherapy. Clinicians note that these side effects are manageable and do not detract from the significant efficacy benefits observed.

Looking forward, the success of Zynyz opens up new avenues for research. Experts emphasize the need to identify biomarkers that can predict which patients are most likely to respond to treatment. Understanding mechanisms of resistance and exploring the optimal duration of immunotherapy will also be critical next steps. The positive results from this trial will likely spur further investigation into novel immunotherapy combinations and targeted agents, continuing the momentum in a field that has been stagnant for far too long.